Histamine infusion induces a selective dopaminergic neuronal death along with an inflammatory reaction in rat substantia nigra.
We have evaluated the effects of a direct infusion of histamine, as mediator of inflammatory response, in substantia nigra, striatum, medial septum, and medial lemniscus. Injection of 100 and 250 nmol of histamine in substantia nigra produced a selective damage in dopaminergic neurons evidenced by the loss of tyrosine hydroxylase mRNA-expressing cells, tyrosine hydroxylase-immunolabeled-positive cell bodies, and dopamine and 3,4-dihydroxyphenylacetic acid levels. In parallel we found an acute inflammatory response manifested by a loss of glial fibrillary acidic protein-immunolabeled astrocytes and, at precisely the same area, an activation of microglia. In the striatum, only high doses (500 nmol) produced an evident terminal degeneration. The selective neurotoxicity of histamine for dopaminergic cells was demonstrated by the unaltered transcription of glutamic acid decarboxylase mRNA in substantia nigra. Moreover, intraseptal injection of 100 nmol of histamine failed to alter the pattern of choline acetyltransferase mRNA-expressing cells, and intraparenchymal injection of histamine in medial lemniscus failed to alter the pattern of serotonin-immunolabeled cells. We conclude that the substantia nigra is highly sensitive to histamine-derived neurotoxicity, where inflammatory processes mediated by histamine could be important in the pathological changes that lead to dopaminergic neuronal damage after histamine infusion.
Vizuete
M L
ML
Departamento de Bioquimica, Bromatologia, Toxicologia, y Medicina Legal, Universidad de Sevilla, Sevilla, Spain.
Merino
M
M
Venero
J L
JL
Santiago
M
M
Cano
J
J
Machado
A
A
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001253:Astrocytes / Q000166:cytology / Q000187:drug effects; D002795:Choline O-Acetyltransferase / Q000235:genetics; D003342:Corpus Striatum / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D004298:Dopamine / Q000378:metabolism*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis; D005968:Glutamate Decarboxylase / Q000235:genetics; D006632:Histamine / Q000008:administration & dosage / Q000494:pharmacology*; D007249:Inflammation; D007263:Infusions, Parenteral; D007527:Isoenzymes / Q000235:genetics; D008297:Male; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D051381:Rats; D020665:Septum of Brain / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D013378:Substantia Nigra / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D014446:Tyrosine 3-Monooxygenase / Q000235:genetics
D005904:Glial Fibrillary Acidic Protein; D007527:Isoenzymes; D012333:RNA, Messenger; D015102:3,4-Dihydroxyphenylacetic Acid; D006632:Histamine; D014446:Tyrosine 3-Monooxygenase; D002795:Choline O-Acetyltransferase; D005968:Glutamate Decarboxylase; C402565:glutamate decarboxylase 1; D004298:Dopamine